LONDON, ENGLAND — April 30, 2002 — New treatment option for exercise-induced asthma licensed in the UK AstraZeneca UK Ltd announced today that its long-acting bronchodilator Oxis® Turbohaler® (eformoterol) has received approval from the Medicines Control Agency (MCA) for use in prevention of exercise-induced asthma (EIA) in adults and children (six years and older).
Oxis Turbohaler can be taken before exercise or other physical activity. Due to its rapid onset of action a patient can feel the effect within minutes of inhalation(1). The long-lasting action of Oxis provides up to 12 hours protection(1) against symptoms of asthma such as shortness of breath, wheezing and chest tightness, all of which can be triggered by exertion. Eformoterol has been shown to provide significantly better protection against exercise-induced asthma for up to 12 hours compared to short-acting bronchodilators in children(2,3) and adults(4). In a trial in adult athletes, Oxis Turbohaler was shown to be effective in protecting against EIA as early as 15 minutes after inhalation(5).
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!